Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

Exclusion Criteria

• •Currently taking or have taken a GLP -1 agent (e.g., Byetta®, Victoza®) within the past year.
• •Subjects who have previously received PB1023.
• •Known allergy or serious adverse effect to an approved or investigational GLP-1 receptor analog/agonist.
• •Serious Infection within 60 days of admission.
• •Donation or loss of greater than 400 mL of blood 56 days prior to enrollment.
• •Unstable cardiovascular disease defined as per protocol.
• •Clinically significant hepatic dysfunction defined as per protocol.
• •Female subjects who are pregnant, trying to become pregnant or lactating.
• •Known history of or active alcohol or drug abuse within 12 months prior to Screening or positive alcohol and/or drug screen.
• •Positive for Human Immunodeficiency Virus (HIV) antibodies, Hepatitis B surface antigen (HBsAg) or Hepatitis C Virus (HCV) antibodies.
• •Participating in any other study at time of screening other than observational studies or have received any other investigational drug or device within 30 days or 5 half-lives prior to dosing or are taking part in a non-drug study which in the opinion of the Investigator would interfere with the outcome of the study.